tailieunhanh - Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials

Rapid improvements in health and nutrition in developing countries may be ascribed to specific, deliberate, health- and nutrition-related interventions and to changes in the underly- ing social, economic, and health environments. This chapter is concerned with the contribution of specific interventions, while recognizing that improved living standards in the long run provide the essential basis for improved health. Consideration of the environment as the context for interven- tions is crucial in determining their initiation and in modifying their effect, and it must be taken into account when assessing this effect. Undoubtedly much change has stemmed from scientific advances, immunization being a prominent case. However, the organizational aspects of health and nutrition protection are equally. | ADHD Atten Def Hyp Disord 2011 3 335-349 DOI s12402-011-0066-y ORIGINAL ARTICLE Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials Alexander Schacht Rodrigo Escobar Thomas Wagner Peter M. Wehmeier Received 20 June 2011 Accepted 19 September 2011 Published online 11 October 2011 The Author s 2011. This article is published with open access at Abstract Our aim was to evaluate the psychometric properties of the generic quality of life QoL scale Child Health and Illness Profile-Child Edition CHIP-CE by means of a combined analysis of atomoxetine clinical trials in children and adolescents with attention-deficit hyper-activity disorder ADHD . Individual patient-level data from five clinical trials were included in the combined analysis. Psychometric properties of the CHIP-CE were explored in terms of internal consistency and structure. Patients n 794 aged between 6 and 15 years mean with mean baseline ADHD Rating Scale of were included. On average SD Trial registration This is a combined analysis of five already published clinical trials. Preliminary results of this analysis have been presented at the EPA meeting 2009. The following publication is based on the same data base but focuses on the clinical-relevant treatment differences and does not contain the psychometrical evaluation of the scale see citation Escobar et al. 2010 . A. Schacht Lilly Deutschland Global Statistical Sciences Werner-Reimers-Str. 2-4 61350 Bad Homburg Germany e-mail schacht_alexander@ R. Escobar Neuroscience Products Medical Science Lilly Research Laboratories Sannomiya Plaza Bldg. 7-1-5 Isogamidori Chuo-ku Kobe 651-0086 Japan e-mail escobar_rodrigo@ T. Wagner Trilogy Writing Consulting GmbH Falkensteiner Str. 77 60322 Frankfurt Germany items were missing for the whole CHIP-CE. The internal consistency of the CHIP-CE assessed by .